Description
The identification of genetic risk factors for Alzheimer’s Disease (AD) provides additional to support that multiple pathways contribute to its onset and progression. However, the metabolomic and lipidomic profiles altered among carriers of distinct genetic risk factors is not fully understood. The study of the metabolome can provide a direct image of dysregulated patterns in an organism, providing information on direct targets for therapeutic treatments. High-throughput metabolomic and lipidomic data for 880 analytes was generated from parietal brain tissue from 423 AD donors and neuropathology free controls using the Metabolon Precision Metabolomics platform.
Sex
Total number of samples: 436
Female 257 58.9 %
Male 179 41.1 %
Race
Total number of samples: 436
| American Indian/Alaska Native | 1 |
| Black or African American | 20 |
| White | 415 |
Ethnicity
Total number of samples: 436
Not Applicable/Not Available
436
100.0%
Diagnosis
Total number of samples: 436
| Alzheimer's Disease and Related Dementias (ADRD) | ||
|---|---|---|
| Control | 26 | 6.0% |
| Case | 397 | 91.1% |
| Other | 13 | 3.0% |
APOE
Total number of samples: 436
- 2321 (4.8%)
- 2419 (4.4%)
- 33171 (39.2%)
- 34165 (37.8%)
- 4437 (8.5%)
- NA23 (5.3%)